Jan. 9 at 6:44 PM
TD Cowen⬆️the PT on
$RYTM to
$130 from
$120 while keeping a Buy rating.
$SLNO $AARD
Here's what TD Cowen had to say:
RYTM announced prelim Q4 rev of
$57MM (+11% Q/Q), beating consensus of
$55MM and our
$54MM.
RYTM will report topline data from both the Japanese HO cohort and the Ph III EMANATE trial in Q1:26.
We expect approval of Imcivree in HO on/before the March 20 PDUFA.
Based on Dec's POC data in PWS, our model now includes conservative PWS rev. estimates with a
P.T. of
$130 (previously
$120). Remain Buy.
